News Conference News ACC 2024 Icosapent Ethyl Lowers CV Risk Across Lp(a) Range: REDUCE-IT Todd Neale March 27, 2024
News Conference News Intermittent Fasting Study Sparks Debate Over Increases in CV Mortality Michael O'Riordan March 22, 2024
News Daily News Peer Coaching May Help With BP Control in Rural Black Populations Todd Neale March 22, 2024
News Daily News FDA Approves Aprocitentan for Inadequately Controlled Hypertension Michael O'Riordan March 20, 2024
News Conference News CRT 2024 SAFE-MCS: Monitoring System Intercepts Bleeding in High-risk PCI L.A. McKeown March 15, 2024
News Conference News CRT 2024 Mixed Bag With DCBs for In-Stent Restenosis, Small Coronary Arteries L.A. McKeown March 14, 2024
News Daily News Decades After WHI: Calcium, Vitamin D Linked to Different CVD, Cancer Outcomes Caitlin E. Cox March 12, 2024
News Daily News Patients With CKD Remain Underrepresented in Trials of CV Meds Todd Neale March 08, 2024
News Conference News THT 2024 Small Study Hints at Apixaban’s Potential in LVAD-Treated Patients Michael O'Riordan March 07, 2024
News Daily News Plastic Debris Found in Carotid Plaque Linked to More Adverse CV Events L.A. McKeown March 06, 2024
News Daily News DISCHARGE Data Reassure on Use of CCTA in Older Chest-Pain Patients Michael O'Riordan March 04, 2024
News Opinion Editor's Corner TCTMD’s Top 10 Most Popular Stories for February 2024 Shelley Wood March 01, 2024
News Daily News Agent Coronary DCB Gets FDA Approval for In-Stent Restenosis L.A. McKeown March 01, 2024
News Daily News High-Risk ‘Clues’ Add Heft to Calcium Scores in Primary Prevention Michael O'Riordan February 29, 2024
News Daily News Living Near Bars, Restaurants Linked to Greater Likelihood of HF L.A. McKeown February 29, 2024
News Daily News High Lp(a) Levels Harmful in Patients With and Without ASCVD Michael O'Riordan February 27, 2024
News Daily News One in Three Overweight MI Patients May Benefit From Semaglutide Todd Neale February 26, 2024
News Daily News Mechanism’s Mojo: ‘Obvious’ CV Therapies More Likely to Be Seen as Effective Michael O'Riordan February 23, 2024